Gilead (NSDQ:GILD) subsidiary Kite will collaborate with Appia Bio (Culver City, Calif.) to develop engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.  To that end, they have entered into a collaboration and license agreement to develop HSC-derived cell therapies for hematological malignancies.  Under the agreement, Appia Bio will lead preclinical and…